Evaluation And Prevention Femoral Periprosthetic Bone Loss Following Cementless Total Hip Arthroplasty: A Randomized, Controlled, Prospective Research

Objective:To explore regularity in six months femoral periprosthetic bone loss soon after cementless total hip arthroplasty. To evaluate the effects of treatment combination Fosamax with Caltrate D and Alpha D3 and the effects of the other combination Calcitonin with Caltrate D and Alpha D3 on femoral periprosthetic bone loss following cementless THA. To provide an effective cyclie therapy in clinical to suppress femoral periprosthetic bone loss after cementless THA.Methods:The study investigated 45 patients operated cementless THA between January 2010 and October 2010 in the Department of Orthopaedics Surgery, the first affiliate hospital of Jinan university. All cases were in accordance with the section standards and satisfied with followed up 6 moths, prospective, randomized with operation date:the control group, the first group combination Miacalcic with Caltrate D and Alpha D3, the second group combination Fosamax with Caltrate D and Alpha D3. The two therapy groups were treated for 6 months. All cases were measured with dual energy X-ray absorptiometry (DEXA) including femoral periprosthetic Gruen zones 1-7 and systemic bone and lumbar bone at 2 weeks,1 months,3months,6months postoperative cementless THA. The staistical analyses were performed using SPSS 13.0 software (version 13.0; SPSS Inc, Chicago, IL, USA).Results:In the cotrolled group there was significant temporal bone mineral density (BMD) decreases measured in femoral periprosthetic Gruen zones 1,2,6,7 but the significant temporal BMD increases measured in femoral periprosthetic Gruen zone 4 and no significant temporal BMD decreases measured in Gruen zones 3,5. Compared the cotrolled group, in the two therapy groups there were all significant temporal BMD increases measured in all femoral periprosthetic Gruen zones and the average BMD was higher than the cotrolled group at 6 months postoperative cementless THA. Compared the two therapy groups, there was significant temporal BMD increases measured in Gruen zones 1,2,3,6,7 in the group combination Fosamax with Caltrate D and Alpha D3. Alao, The average BMD was higher than the combination Miacalcic with Caltrate D and Alpha D3. Conclusions:Femoral periprosthetic BMD is measured significant increases in Gruen zone 4, no significant change in Gruen zones 3,5 and significant decreases in Gruen zones 1,2,6,7 in 6 months after cementless THA. The combination Fosamax with Caltrate D and Alpha D3 and the other combination Miacalcic with Caltrate D and Alpha D3 all can have significant effect in suppressing femoral periprosthetic bone loss after cementless total hip arthroplasty in 3—6 months postoperative cementless THA. The combination Fosamax with Caltrate D and Alpha D3 has better effect than the other combination. As the result, the combination Fosamax with Caltrate D and Alpha D3 will be a favorable method in clinical for the treatment of suppressing femoral periprosthetic bone loss soon after cementless total hip arthroplasty.